How FDA wholesale distributor reporting works
Since 2015, the Drug Supply Chain Security Act (DSCSA) of 2013 has required every wholesale distributor of prescription drugs in the United States to report its state licences to the FDA each year, along with any significant disciplinary action. The FDA publishes the results in its Wholesale Distributor and Third-Party Logistics Providers Reporting database. Third-party logistics providers (3PLs) report under the same system but are flagged separately, because they store and ship product without taking ownership of it.
The database is organised by licence, not by company. A national distributor that ships into every state from a single warehouse appears once for each state licence, and a company with several distribution centers multiplies that again. In the FDA's WDD entries, roughly 31,000 licence rows resolve to about 1,960 distinct facilities and about 1,300 distinct legal entities. That gap is why trade-relations and compliance teams usually need the data rolled up before it is useful.
What a reported licence tells you
- Legal name and DBA – the entity that holds the licence, which is often a subsidiary rather than the brand a pharmacy recognises.
- Facility address – the physical warehouse or office the licence covers.
- Licence state and number – the state that issued the licence; non-resident licences show where a distributor is allowed to ship, not where it sits.
- Expiration date and reporting year – a licence that has lapsed or was not reported in the latest cycle is a flag worth checking before onboarding.
Who is in the population
The reporting population runs from the three national full-line wholesalers and their many subsidiaries, through regional full-line distributors that serve independent pharmacies, to secondary wholesalers focused on generics, specialty distributors for oncology and biologics, repackagers that also distribute, and manufacturers that hold wholesale licences to sell their own products. For a market-access team, the regional and secondary tiers are usually where the unknown trading partners are.
| Tier | Typical customers | Why it matters |
|---|---|---|
| National full-line | Chains, health systems, independents | Most volume, few legal entities but many licences |
| Regional full-line | Independent pharmacies in a home region | Primary supplier for many independents |
| Secondary / generics | Independents topping up or buying generics | Price-driven; licensed in many states from one site |
| Specialty | Clinics, oncology practices, specialty pharmacies | Cold chain and limited-distribution products |
Checking a trading partner under DSCSA
DSCSA allows a manufacturer, distributor or dispenser to transact only with authorized trading partners. For a wholesale distributor, that means a valid state licence and a current report to the FDA. Since the enhanced drug distribution security requirements took full effect, partners also exchange transaction information electronically at the package level, so qualifying a new distributor now involves confirming its licence status, its EPCIS connectivity and its verification process for suspect product. Accreditation from the NABP Drug Distributor Accreditation program is a common additional signal that buyers look for.
Practical notes for using the data
- Group by legal entity first, then by parent company; subsidiaries of the same group often report under different names.
- Count resident versus non-resident licences to see whether a distributor is truly regional or ships nationally from one site.
- Compare the reporting year across rows; a distributor that stopped reporting may have closed, merged or lost a licence.
- Keep 3PLs separate from distributors when the goal is a sales or trading-partner list, because a 3PL does not buy product.